Literature DB >> 25939438

Relationship between serum visfatin levels and coronary slow-flow phenomenon.

Huseyin Altug Cakmak1, Serkan Aslan2, Ahmet Arif Yalcin2, Ibrahim Faruk Akturk2, Burce Yalcin3, Fatih Uzun2, Derya Ozturk2, Mehmet Erturk2, Mehmet Gul2.   

Abstract

BACKGROUND: Increased levels of visfatin, a novel adipocytokine, are reported in atherosclerosis, obesity, and type 2 diabetes. The aim of the present study was to investigate the relationship between coronary slow flow (CSF) and visfatin in patients undergoing elective coronary angiography for suspected coronary artery disease. PATIENTS AND METHODS: A total of 140 recruited participants (90 patients with CSF and 50 controls) were divided into two groups according to their coronary flow rates. Coronary flow was quantified by thrombolysis in myocardial infarction (TIMI) frame count (TFC).
RESULTS: Serum visfatin levels were higher in the CSF group than in the control group (3.29 ± 1.11 vs. 2.70 ± 1.08 ng/ml, p = 0.003). A significant correlation was found between TFC and visfatin (r = 0.535, p < 0.001). The area under the receiver operating characteristic curve was 0.720 (95 % confidence interval, 0.622-0.817, p < 0.001) for visfatin in the diagnosis of CSF. If a cut-off value of 2.59 ng/ml was used, higher levels of visfatin could predict the presence of CSF with 78.9 % sensitivity and 64.0 % specificity.
CONCLUSION: Visfatin levels might be a useful biomarker for predicting CSF in patients undergoing diagnostic coronary angiography.

Entities:  

Keywords:  Biomarker; Coronary artery disease; Coronary slow flow; Thrombolysis in myocardial Infarction frame count; Visfatin

Mesh:

Substances:

Year:  2015        PMID: 25939438     DOI: 10.1007/s00059-015-4313-4

Source DB:  PubMed          Journal:  Herz        ISSN: 0340-9937            Impact factor:   1.443


  50 in total

1.  Is slow coronary flow associated with inflammation?

Authors:  Jian-Jun Li; Bo Xu; Zi-Cheng Li; Jie Qian; Bing-Qi Wei
Journal:  Med Hypotheses       Date:  2005-11-08       Impact factor: 1.538

2.  ESC/EAS Guidelines for the management of dyslipidaemias: the Task Force for the management of dyslipidaemias of the European Society of Cardiology (ESC) and the European Atherosclerosis Society (EAS).

Authors:  Zeljko Reiner; Alberico L Catapano; Guy De Backer; Ian Graham; Marja-Riitta Taskinen; Olov Wiklund; Stefan Agewall; Eduardo Alegria; M John Chapman; Paul Durrington; Serap Erdine; Julian Halcox; Richard Hobbs; John Kjekshus; Pasquale Perrone Filardi; Gabriele Riccardi; Robert F Storey; David Wood
Journal:  Eur Heart J       Date:  2011-06-28       Impact factor: 29.983

3.  Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus.

Authors:  Miao-Pei Chen; Fu-Mei Chung; Dao-Ming Chang; Jack C-R Tsai; Han-Fen Huang; Shyi-Jang Shin; Yau-Jiunn Lee
Journal:  J Clin Endocrinol Metab       Date:  2005-10-18       Impact factor: 5.958

4.  Pre-B cell colony-enhancing factor/visfatin, a new marker of inflammation in rheumatoid arthritis with proinflammatory and matrix-degrading activities.

Authors:  Fabia Brentano; Olivier Schorr; Caroline Ospelt; Joanna Stanczyk; Renate E Gay; Steffen Gay; Diego Kyburz
Journal:  Arthritis Rheum       Date:  2007-09

5.  Elevated plasma endothelin-1 levels in coronary sinus during rapid right atrial pacing in patients with slow coronary flow.

Authors:  Hasan Pekdemir; Gurbuz Polat; V Gökhan Cin; Ahmet Camsari; Dilek Cicek; M Necdet Akkus; Oben Doven; M Tuna Katircibasi; Necati Muslu
Journal:  Int J Cardiol       Date:  2004-10       Impact factor: 4.164

6.  Comparison of exercise QRS amplitude changes in patients with slow coronary flow versus significant coronary stenosis.

Authors:  Muhsin Turkmen; Irfan Barutcu; Ali Metin Esen; Osman Karakaya; Ozlem Esen; Yelda Basaran
Journal:  Jpn Heart J       Date:  2004-05

7.  Visfatin (nampt) and ghrelin as novel markers of carotid atherosclerosis in patients with type 2 diabetes.

Authors:  N P E Kadoglou; N Sailer; A Moumtzouoglou; A Kapelouzou; H Tsanikidis; I Vitta; C Karkos; P E Karayannacos; T Gerasimidis; C D Liapis
Journal:  Exp Clin Endocrinol Diabetes       Date:  2009-10-15       Impact factor: 2.949

Review 8.  Minireview: adiposity, inflammation, and atherogenesis.

Authors:  Christopher J Lyon; Ronald E Law; Willa A Hsueh
Journal:  Endocrinology       Date:  2003-06       Impact factor: 4.736

9.  Clinical manifestations of slow coronary flow from acute coronary syndrome to serious arrhythmias.

Authors:  Beata Wozakowska-Kapłon; Justyna Niedziela; Paweł Krzyzak; Sebastian Stec
Journal:  Cardiol J       Date:  2009       Impact factor: 2.737

10.  Cardiorespiratory capacity is associated with favourable cardiovascular risk profile in patients with Type 2 diabetes.

Authors:  Nikolaos P E Kadoglou; Fotios Iliadis; Nikoleta Angelopoulou; Nikolaos Sailer; Grigorios Fotiadis; Kleon Voliotis; Ioulia Vitta; Christos D Liapis; Miltiadis Alevizos
Journal:  J Diabetes Complications       Date:  2008-04-16       Impact factor: 2.852

View more
  4 in total

1.  Low Serum Adropin Levels are Associated with Coronary Slow Flow Phenomenon.

Authors:  Zi-Wen Zhao; Yin-Gang Ren; Jun Liu
Journal:  Acta Cardiol Sin       Date:  2018-07       Impact factor: 2.672

2.  Visfatin associated with major adverse cardiovascular events in patients with acute myocardial infarction.

Authors:  Meifan Zheng; Nan Lu; Meixia Ren; Haifeng Chen
Journal:  BMC Cardiovasc Disord       Date:  2020-06-05       Impact factor: 2.298

3.  Increased circulating soluble urokinase-type plasminogen activator receptor (suPAR) levels in patients with slow coronary flow.

Authors:  Acar Emrah; İzgi İbrahim Akın; İzci Servet; Kahyaoğlu Muzaffer; Yılmaz Mehmet Fatih; Güler Yeliz; Efe Süleyman Çağan; Güler Ahmet; Kılıçgedik Alev; Kırma Cevat
Journal:  Arch Med Sci Atheroscler Dis       Date:  2016-06-22

4.  The relationship of serum visfatin levels with clinical parameters, flow-mediated dilation, and carotid intima-media thickness in patients with ankylosing spondylitis

Authors:  Rabia Aydoğan Baykara; Adem Küçük; Ayça Tuzcu; Göksel Tuzcu; Erkan Cüre; Ali Uğur Uslu; Ahmet Omma
Journal:  Turk J Med Sci       Date:  2021-08-30       Impact factor: 0.973

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.